Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD
TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.
Bristle Discount Link (Oral Microbiome Quantification):
ConquerAging15
https://www.bmq30trk.com/4FL3LK/GTSC3/
Quantify Discount Link (At-Home Blood Testing):
Elon Musk’s Neuralink is under federal investigation for potential animal-welfare violations after staff complaints about rushed animal testing. Ana Kasparian discusses on The Young Turks. Watch TYT LIVE on weekdays 6–8 pm ET. http://youtube.com/theyoungturks/live.
“Elon Musk’s Neuralink, a medical device company, is under federal investigation for potential animal-welfare violations amid internal staff complaints that its animal testing is being rushed, causing needless suffering and deaths, according to documents reviewed by Reuters and sources familiar with the investigation and company operations.
Neuralink Corp is developing a brain implant it hopes will help paralyzed people walk again and cure other neurological ailments. The federal probe, which has not been previously reported, was opened in recent months by the U.S. Department of Agriculture’s Inspector General at the request of a federal prosecutor, according to two sources with knowledge of the investigation. The probe, one of the sources said, focuses on violations of the Animal Welfare Act, which governs how researchers treat and test some animals.”
The largest online progressive news show in the world. Hosted by Cenk Uygur and Ana Kasparian. LIVE weekdays 6–8 pm ET.
“The likelihood of a cyber-attacks on Twitter feel very high right now and their ability to be able to counteract that feels very low,” Radcliffe said. “The amount of information that they have on users is considerable and I think that that’s a potential source of concern, particularly in countries in the Middle East and other places where once the information is on the open market and in the public domain it could potentially be harmful to users.”
Partnering with individuals or groups close to authoritarian regimes raises concerns over how Twitter might react should it be pressured by supply information on dissidents or to quell opposition speech. They also raise questions about Musk’s potential conflict of business interests concerning Tesla and Space X’s availability in certain markets.
Such questions have already been brought up by at least one member of the US Congress. But experts say they’re much more concerned about data security should Twitter go under.
“This is the break of dawn,” declared Slush CEO Eerika Savolainen, kicking off this year’s event and its messages of hope, renewal and change. The sense of positivity was palpable among the 12 000 attendees, including 4 600 startups and 2 600 investors, gathered at the Helsinki Exhibition Centre.
Since its inaugural event in 2008, which attracted 250 participants, Slush has become a landmark in the tech industry’s event calendar. It has developed a secret sauce featuring a student-led organisation, relaxed atmosphere and knack for attracting big names in tech both on stage and to Helsinki in general. At the same time, it has been able to maintain its mission to create and help ground-breaking entrepreneurs.
Text messages have emerged about SBF trying to depeg USDT.
In text messages obtained by the NYT, CZ said that SBF was using Alameda to place trades designed to destabilize Tethter (USDT).
NASA’s Orion spacecraft is on course for its return to Earth on Sunday, Dec. 11. The spacecraft made its second and final close approach to the Moon at 10:43…
Watch live as our mega Moon rocket launches an uncrewed Orion spacecraft on a six-week mission around the Moon and back to Earth. NASA is targeting Wednesday, Nov. 16, for the launch of the Artemis I Moon mission during a two-hour launch window that opens at 1:04 a.m. EST (0604 UTC). During #Artemis I, Orion will lift off aboard the Space Launch System (SLS) rocket, and travel 280,000 miles (450,000 km) from Earth and 40,000 miles (64,000 km) beyond the far side of the Moon, carrying science and technology payloads to expand our understanding of lunar science, technology developments, and deep space radiation. Through Artemis missions, NASA will land the first woman and the first person of color on the Moon, paving the way for a long-term lunar presence and serving as a steppingstone to send astronauts to Mars. We are going.
PLEASE SUBSCRIBE!! https://www.youtube.com/user/SteviePAX
Become a Channel Member https://www.youtube.com/channel/UCNj6DsIsOi-DHORB-0MGlGQ/join.
INSTAGRAM-https://www.instagram.com/steviepax/?hl=en.
Life is short, but Tomorrow Bio explains how cryonics is a good option that can offer more time for your lifespan. Check out how below!
If you’re expecting monoclonal antibody treatments to save you from getting more severe outcomes like death should you get Covid-19, it may be time to rethink that strategy. A letter published in The Lancet Infectious Diseases journal on November 18 detailed how many of the currently spreading Omicron subvariants, namely the BA.4.6, BA.2.75.2, and BJ.1 ones, appear to be resistant to most available monoclonal antibody treatments. And the BQ.1.1 Omicron subvariant, which has become one of the two dominant versions of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the U.S., seems resistant to all of the available monoclonal antibody treatments. Yes, all of them, as in every single one.
BQ certainly doesn’t stand for “be quiet,” as the BQ.1.1 subvariant is now causing a commotion, being responsible for an estimated 24.2% of all new reported Covid-19 cases over the past week while the not-too-different BQ.1 subvariant has been the culprit behind 25.5% of them, according to the Centers for Disease Control and Prevention (CDC). If you do the math, that means that these two Omicron subvariants are now comprising over half of all reported Covid-19 cases, meaning that they have overtaken the BA.5 as the “alpha-dog” of SARS-CoV-2 versions. Therefore, you can probably no longer rely on any type of monoclonal antibody should you get Covid-19. That’s certainly bad news for anyone not able to get enough protection from Covid-19 vaccination such as those who have very weak immune systems.
You know that 1997 Backstreet Boys song that goes “everybody, yeah?” Well, looks like the latest 2022 Covid-19 coronavirus Omicron subvariants have been going, “antibody, no-oh.” So much for the argument that other Covid-19 precautions are not needed because monoclonal antibodies are available. Even back in 2020 and 2021 when monoclonal antibody treatments seemed to work against the then-circulating previous versions of the virus, such an argument held water about as well as a Brillo pad thong since relying on any single Covid-19 precaution or treatment has always been a foolhardy approach. Doing so was akin to telling someone, “since you have underwear on, why do you need pants or a skirt or a kilt?” Ever since the start of the pandemic, real pandemic experts have continued to advocate for more of a “Swiss cheese” approach that entails always layering on different Covid-19 interventions simultaneously because each single intervention has its holes.
😗
BOSTON — Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.
The investigational drug, described in a report published today in Science Advances, is not an antibody, but a related molecule known as an ACE2 receptor decoy. Unlike antibodies, the ACE2 decoy is far more difficult for the SARS-CoV-2 virus to evade because mutations in the virus that would enable it to avoid the drug would also reduce the virus’s ability to infect cells. The Dana-Farber scientists found a way to make this type of drug neutralize coronaviruses more potently in animals infected with COVID-19 and to make it safe to give to patients.
This report comes at a time when antibody drugs used to treat COVID-19 have lost their effectiveness because the viral spike protein has mutated to escape being targeted by the antibodies.
